Artivion: Q2 Earnings Snapshot
Artivion, Inc. (AORT) reported Q2 revenue of $125.8 million and a net loss of $13.5 million, or 28 cents per share, versus a profit a year earlier. Adjusted earnings were 13 cents per share. The company expects full-year revenue of $480 million to $496 million. Shares fell sharply year to date.
How this was made
The 30-second read
Why it matters
Traders can update models using the provided Q2 revenue and the $480M-$496M full-year revenue range, and reassess risk given the year-to-date drawdown.
Market read
Fresh quarterly results and explicit full-year revenue guidance are the main tradable inputs, especially after a large YTD decline.
What to watch
The article omits cash flow, gross margin, backlog, and whether guidance reflects specific product or reimbursement changes, which are key drivers for device-name re-rating.
Background
Artivion is a biological medical device maker; this is a Q2 earnings snapshot with reported loss and a full-year revenue outlook.
Ticker impact
Artivion reported Q2 revenue of $125.8M, a loss of $13.5M, and guided full-year revenue to $480M-$496M.
Likely choppy to downside-biased if investors focus on the Q2 loss, but the explicit full-year revenue range can stabilize expectations.
The article includes both reported quarterly figures and a forward revenue range, but lacks consensus/beat-miss context and margin/cash-flow details.
Market effects
Biological medical device peers may see read-through on demand and margin trajectory, but the article provides no competitive or regulatory catalysts.
Limited, as the disclosure is company-specific with no broader regional macro or policy linkage.
Low, since the news is a US-listed company earnings and guidance update without international deal/regulatory developments.
Counterpoint
Investors may discount the quarterly loss if adjusted EPS and the guided full-year revenue range suggest improving operating leverage later in the year.
Key entities
- companyArtivion, Inc.
Reported Q2 loss and revenue, and issued full-year revenue guidance of $480M-$496M.
